New pill helps smokers kick the habit in major trial
NCT ID NCT05206370
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tested cytisinicline, a plant-based pill, in 792 adult smokers who wanted to quit. Participants took the pill or a placebo for 6 or 12 weeks, plus brief behavioral support. The study measured smoking abstinence using carbon monoxide tests. Results showed that cytisinicline helped more people quit smoking compared to placebo, offering a potential new option for smoking cessation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cytisinicline (also known as cytisine), a plant-based pill to reduce nicotine cravings
What this could lead to
If successful, this could provide a new, affordable, and effective medication to help people quit smoking, reducing smoking-related diseases.
What could go wrong
This is a completed phase 3 trial, but results may not apply to all smokers. Long-term abstinence beyond 24 weeks is not yet confirmed, and side effects like nausea or insomnia are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOKING CESSATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Accel Research Sites - DeLand Clinical Research Unit
DeLand, Florida, 32720, United States
-
Affinity Health Corp
Oak Brook, Illinois, 60523, United States
-
Alliance for Multispecialty Research, LLC
Fort Myers, Florida, 33912, United States
-
Aventiv Research Inc
Columbus, Ohio, 43212, United States
-
Clinical Research Associates, Inc.
Nashville, Tennessee, 37203, United States
-
Global Medical Institutes LLC; Princeton Medical Institute
Princeton, New Jersey, 08540, United States
-
Health Research of Hampton Toads, Inc
Newport News, Virginia, 23606, United States
-
Intend Research
Norman, Oklahoma, 73069, United States
-
Jacksonville Center for Clinical Research
Jacksonville, Florida, 32216, United States
-
MediSphere Medical Research Center, LLC
Evansville, Indiana, 47714, United States
-
Trial Management Associates, LLC
Wilmington, North Carolina, 28403, United States
-
Velocity Clinical Research, Inc.
Cleveland, Ohio, 44122, United States